Newsroom

Our central location for research news and other stories of related information can be found here.

Wednesday, December 7, 2011

The Christ Hospital First in U.S. to Implant New Bare Metal Stent

Physicians at The Christ Hospital are first in the U.S. to implant the OMEGA bare metal stent as part of a clinical trial sponsored by Boston Scientific. This trial will test the OMEGA(tm) Platinum Chromium Bare-Metal Coronary Stent System for safety and efficacy in the treatment of coronary artery disease. Dean Kereiakes, MD, principal investigator for the study at The Christ Hospital, treated the first U.S. patient in the study. The patient, an 68-year-old man from Harrison, Ohio, is doing well and is available for interview.

Read the full story (PDF)

Wednesday, November 9, 2011

The Christ Hospital is First in U.S. to Implant and is the Highest Enrolling Site for Investigational Second Generation MR-Conditional Pacemaker through Clinical Trial at Lindner Research Center

Edward J. Schloss, M.D., medical director of electrophysiology at The Christ Hospital, was the first in the U.S. to implant the Advisa MRI SureScan® Pacing System, Medtronic’s second-generation pacemaker system, as part of a clinical trial offered through The Carl and Edyth Lindner Center for Research and Education. The study is investigating whether this new system, designed to be compatible with magnetic resonance imaging (MRI) scanners, is safe and effective for use in the MRI environment on any body region.

Read the full story (PDF)

The Christ Hospital First in Ohio to Treat Patient with Drug-Coated Balloon

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) have treated the first patient in the state of Ohio with the Moxy™ Drug Coated Balloon as part of LEVANT 2, a global, multi-center, randomized clinical trial evaluating the safety and efficacy of this device for the treatment of peripheral arterial disease (PAD). Monica Hunter, M.D., interventional cardiologist at The Christ Hospital and principal investigator at the Lindner Research Center, performed the case. The patient is doing well and has been discharged home.

Read the full story (PDF)

Tuesday, November 8, 2011

Boston Scientific Platinum Chromium ION™ Stent Demonstrates Positive Outcomes in PERSEUS Clinical Program

Boston Scientific Corporation (NYSE: BSX) reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION™ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents. Results were presented today by PERSEUS clinical program Principal Investigators Louis Cannon, M.D., of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Michigan, and Dean Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco.

Read the full story

Wednesday, October 5, 2011

The Christ Hospital First in Ohio to Treat Patient with Drug-Coated Balloon

Physicians at The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) have treated the first patient in the state of Ohio with the Moxy™ Drug Coated Balloon as part of LEVANT 2, a global, multi-center, randomized clinical trial evaluating the safety and efficacy of this device for the treatment of peripheral arterial disease (PAD). Monica Hunter, MD, interventional cardiologist at The Christ Hospital and principal investigator at the Lindner Research Center, performed the case. The patient is doing well and has been discharged home.

Read the full story (PDF)

Tuesday, September 20, 2011

United Therapeutics faces bleak future for oral Remodulin approval with disappointing PAH results, lack of physician enthusiasm

United Therapeutics' (NASDAQ:UTHR) oral Remodulin (treprostinil) faces a bleak future, experts said. The company still plans to file for FDA approval for the pulmonary arterial hypertension (PAH) treatment indication, despite its recent failure in the pivotal Phase III Freedom-C2 study. The failed combination therapy study (oral Remodulin combined with other first line PAH therapies) was described by physicians as the pivotal study which would likely mirror its realistic treatment setting.

Tuesday, June 21, 2011

The Christ Hospital First in Cincinnati to Use New Device Designed to Prevent Stroke in Patients with Common Heart Rhythm Disorder

Physicians at The Christ Hospital are the first in Greater Cincinnati to implant the WATCHMAN Left Atrial Appendage Closure device as part of a clinical trial through the Carl and Edyth Lindner Center for Research and Education (Lindner Research Center). The trial is studying the capabilities of the WATCHMAN device to treat patients with atrial fibrillation (AF) who require blood-thinning medications to reduce their risk of stroke. This is a confirmatory study on a prior pivotal study that was completed in June 2008. This study will provide additional information on the safety and efficacy of the device for Food and Drug Administration (FDA) review. Madhukar Gupta, MD, an electrophysiologist with The Christ Hospital, performed the procedure on a 79-year-old woman from Milford, Ohio. The patient is doing well. Both Dr. Gupta and the patient are available for interviews.

Read the full story

Tuesday, May 24, 2011

Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS® 2.25 mm Everolimus-Eluting Coronary Stent System

"The PROMUS Stent has demonstrated outstanding deliverability, low late loss and excellent safety in numerous clinical trials and extensive real-world practice," said Dean J. Kereiakes, MD, FACC, Medical Director, The Christ Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, and Professor of Clinical Medicine, Ohio State University.  "These benefits make the PROMUS 2.25 mm Stent an attractive option for U.S. physicians treating patients with small vessels."

Read the full story

Tuesday, May 10, 2011

Cardiologists with The Christ Hospital are First in Greater Cincinnati Region to Perform Heart Valve Replacement without Open Heart Surgery

Physicians at The Christ Hospital are first to bring pioneering technology to Greater Cincinnati that may provide a treatment option for patients with a common heart valve disorder who do not qualify for surgery. The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (Lindner Research Center) is one of 20+ sites in the U.S. to participate in an investigational research trial using a novel therapy to treat severe aortic stenosis (AS), a condition that affects nearly 1.5 million Americans. The PARTNER (Placement of AoRTic traNscathetER valves) II Trial will evaluate transcatheter aortic valve replacement (TAVR), using the Edwards SAPIEN XT valve, in patients who are considered to be at high risk or inoperable for traditional valve replacement using open-heart surgery. The Christ Hospital is the only PARTNER II study site between Cleveland, Oh. and Atlanta, Ga.

Read the full story

Monday, April 4, 2011

Dean Kereiakes, MD, FACC, Receives Simon Dack Award for Outstanding Scholarship

The editors of the Journal of the American College of Cardiology (JACC) honored Dean Kereiakes, MD, FACC, with the Simon Dack Award for Outstanding Scholarship on Sunday, April 3 at their editorial board meeting in New Orleans, La. The Simon Dack Award, named for the founding editor of JACC, recognizes peer reviewers who assist the journal in its mission of publishing important new clinical information. Since 2006, Dr. Kereiakes has submitted 78 editorial reviews to JACC and JACC Cardiovascular Interventions.

Read the full story (PDF)

Tuesday, March 22, 2011

The Christ Hospital First in Cincinnati to Study Novel Heart Failure Monitoring Device

Physicians with The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital (The Lindner Research Center) are the first in Cincinnati to implant an investigational left atrial pressure (LAP) monitoring device as part of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy (LAPTOP) investigational trial by St. Jude Medical. The device directly tracks pressure within the heart in real time. The pressure measurements are intended to help physicians determine how and when they should adjust a patient’s heart failure (HF) medications. Currently, there is no other means of obtaining LAP measurements outside the clinic or hospital setting. The goal of the trial is to prevent fluid retention in HF patients and also to prevent hospitalization, therefore improving quality of life. A 78-year-old man from Monroe, Ohio was the first patient to receive this device at The Christ Hospital in February, and is doing well. The device was implanted by Jay Schloss, MD, FACC, director of electrophysiology at The Christ Hospital Heart and Vascular Center. Both Dr. Schloss and the patient are available for interviews.

Read the full story